Cargando…

Systemic inflammation is a determinant of outcomes of CD40 agonist–based therapy in pancreatic cancer patients

Agonistic anti-CD40 monoclonal antibody (mAb) therapy in combination with chemotherapy (chemoimmunotherapy) shows promise for the treatment of pancreatic ductal adenocarcinoma (PDA). To gain insight into immunological mechanisms of response and resistance to chemoimmunotherapy, we analyzed blood sam...

Descripción completa

Detalles Bibliográficos
Autores principales:	Wattenberg, Max M., Herrera, Veronica M., Giannone, Michael A., Gladney, Whitney L., Carpenter, Erica L., Beatty, Gregory L.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	American Society for Clinical Investigation 2021
Materias:	Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8021099/ https://www.ncbi.nlm.nih.gov/pubmed/33497362 http://dx.doi.org/10.1172/jci.insight.145389

Ejemplares similares

TNF blockade uncouples toxicity from antitumor efficacy induced with CD40 chemoimmunotherapy
por: Stone, Meredith L., et al.
Publicado: (2021)

Type 1 conventional dendritic cells are systemically dysregulated early in pancreatic carcinogenesis
por: Lin, Jeffrey H., et al.
Publicado: (2020)

Determinants of Homologous Recombination Deficiency in Pancreatic Cancer
por: Wattenberg, Max M., et al.
Publicado: (2021)

Activation of human B cells by the agonist CD40 antibody CP-870,893 and augmentation with simultaneous toll-like receptor 9 stimulation
por: Carpenter, Erica L, et al.
Publicado: (2009)

Agonistic CD40 Antibodies in Cancer Treatment
por: Djureinovic, Dijana, et al.
Publicado: (2021)

CD40/anti-CD40 antibody complexes which illustrate agonist and antagonist structural switches
por: Argiriadi, Maria A., et al.
Publicado: (2019)

Concepts for agonistic targeting of CD40 in immuno-oncology
por: Richards, David M., et al.
Publicado: (2019)

Neoadjuvant Selicrelumab, an Agonist CD40 Antibody, Induces Changes in the Tumor Microenvironment in Patients with Resectable Pancreatic Cancer
por: Byrne, Katelyn T., et al.
Publicado: (2021)

CD40 agonist-induced IL-12p40 potentiates hepatotoxicity
por: Bonnans, Caroline, et al.
Publicado: (2020)

Platinum response characteristics of patients with pancreatic ductal adenocarcinoma and a germline BRCA1, BRCA2 or PALB2 mutation
por: Wattenberg, Max M., et al.
Publicado: (2019)

Sustained Intratumoral Administration of Agonist CD40 Antibody Overcomes Immunosuppressive Tumor Microenvironment in Pancreatic Cancer
por: Liu, Hsuan‐Chen, et al.
Publicado: (2023)

Agonistic Anti-CD40 Antibody Triggers an Acute Liver Crisis With Systemic Inflammation in Humanized Sickle Cell Disease Mice
por: Yalamanoglu, Ayla, et al.
Publicado: (2021)

Next Generation CD40 Agonistic Antibodies for Cancer Immunotherapy
por: Salomon, Ran, et al.
Publicado: (2022)

Platelets as Key Factors in Inflammation: Focus on CD40L/CD40
por: Cognasse, Fabrice, et al.
Publicado: (2022)

Phase 1 dose-escalation study of SEA-CD40: a non-fucosylated CD40 agonist, in advanced solid tumors and lymphomas
por: Coveler, Andrew L, et al.
Publicado: (2023)

Kupffer cells prevent pancreatic ductal adenocarcinoma metastasis to the liver in mice
por: Thomas, Stacy K., et al.
Publicado: (2023)

Novel combination immunotherapy for pancreatic cancer: potent anti‐tumor effects with CD40 agonist and interleukin‐15 treatment
por: Van Audenaerde, Jonas RM, et al.
Publicado: (2020)

Understanding the influence of the tumor microenvironment on macrophage responses to CD40 agonists
por: Luheshi, Nadia, et al.
Publicado: (2014)

Pre-clinical development of the human CD40 agonistic antibody ADC-1013
por: Norlén, Per, et al.
Publicado: (2015)

Injectable Nanoparticle‐Based Hydrogels Enable the Safe and Effective Deployment of Immunostimulatory CD40 Agonist Antibodies
por: Correa, Santiago, et al.
Publicado: (2022)

ADC-1013, an agonistic CD40 antibody optimized for local immunotherapy of cancer
por: Mangsbo, Sara M, et al.
Publicado: (2013)

CD40 Ligand–CD40 Interaction Is an Intermediary between Inflammation and Angiogenesis in Proliferative Diabetic Retinopathy
por: Abu El-Asrar, Ahmed M., et al.
Publicado: (2023)

Dendritic cell vaccination and CD40-agonist combination therapy licenses T cell-dependent antitumor immunity in a pancreatic carcinoma murine model
por: Lau, Sai Ping, et al.
Publicado: (2020)

Agonistic Anti-CD40 Enhances the CD8(+) T Cell Response during Vesicular Stomatitis Virus Infection
por: Zickovich, Julianne M., et al.
Publicado: (2014)

CD40 Agonists Alter the Pancreatic Cancer Microenvironment by Shifting the Macrophage Phenotype toward M1 and Suppress Human Pancreatic Cancer in Organotypic Slice Cultures
por: Lim, Chae Yoon, et al.
Publicado: (2022)

Macrophage-based immunotherapy for the treatment of pancreatic ductal adenocarcinoma
por: Beatty, Gregory L
Publicado: (2013)

Whole body irradiation and agonist anti-CD40 synergize to promote adoptive T cell therapy of resistant murine pancreatic neuroendocrine tumors
por: Ward-Kavanagh, Lindsay, et al.
Publicado: (2015)

Sustained Intratumoral Administration of Agonist CD40 Antibody Overcomes Immunosuppressive Tumor Microenvironment in Pancreatic Cancer (Adv. Sci. 9/2023)
por: Liu, Hsuan‐Chen, et al.
Publicado: (2023)

A Role for CD154, the CD40 Ligand, in Granulomatous Inflammation
por: Villeneuve, Julien, et al.
Publicado: (2017)

IL-15 synergizes with CD40 agonist antibodies to induce durable immunity against bladder cancer
por: Wong, Jeffrey L., et al.
Publicado: (2023)

IL-15 synergizes with CD40 agonist antibodies to induce durable immunity against bladder cancer
por: Wong, Jeffrey L., et al.
Publicado: (2023)

Local immunotherapy based on agonistic CD40 antibodies effectively inhibits experimental bladder cancer
por: Sandin, Linda C, et al.
Publicado: (2014)

Characterization of a Broadly Reactive Anti-CD40 Agonistic Monoclonal Antibody for Potential Use as an Adjuvant
por: Martin, Cameron, et al.
Publicado: (2017)

Adipocytes control hematopoiesis and inflammation through CD40 signaling
por: Reiche, Myrthe E., et al.
Publicado: (2022)

CD40/CD40L expression and its prognostic value in cervical cancer
por: Grazia, G.A., et al.
Publicado: (2023)

Characteristics and clinical trial results of agonistic anti-CD40 antibodies in the treatment of malignancies
por: Li, Da-Ke, et al.
Publicado: (2020)

The human CD40 agonistic antibody ADC-1013 generates immune mediated anti-tumor effects in syngeneic tumor models in hCD40 transgenic mice
por: Mangsbo, Sara M, et al.
Publicado: (2014)

Engineered chimeric antigen receptor-expressing T cells for the treatment of pancreatic ductal adenocarcinoma
por: Beatty, Gregory L
Publicado: (2014)

Efficacy of CD40 Agonists Is Mediated by Distinct cDC Subsets and Subverted by Suppressive Macrophages
por: Murgaski, Aleksandar, et al.
Publicado: (2022)

The CD40 agonist HERA-CD40L results in enhanced activation of antigen presenting cells, promoting an anti-tumor effect alone and in combination with radiotherapy
por: Frankish, Jamie, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_7g3alm0m4o28n6jbkg8djv575v